In a patient with Hermansky‑Pudlak syndrome undergoing surgery, should desmopressin (DDAVP) or tranexamic acid be used to prevent peri‑operative bleeding?

Tranexamic Acid is Preferred Over DDAVP for Hermansky-Pudlak Syndrome Surgical Bleeding Prevention

For patients with Hermansky-Pudlak syndrome (HPS) undergoing surgery, tranexamic acid should be the primary pharmacologic agent, with DDAVP reserved only as an adjunct or when tranexamic acid alone is insufficient, and platelet transfusion should be readily available as the definitive hemostatic intervention.

Rationale for Tranexamic Acid Priority

Evidence-Based Superiority

The most recent perioperative guidelines consistently recommend tranexamic acid as first-line prophylaxis for high-risk bleeding scenarios 1, 2, 3. Tranexamic acid (10-15 mg/kg loading dose followed by 1-5 mg/kg/hour infusion) is specifically recommended for prophylaxis in patients at high risk for excessive bleeding 1. The 2024 ISTH guidelines on bleeding disorders of unknown cause demonstrate that tranexamic acid is the preferred prophylactic agent for both minor (79% of clinicians) and major surgery (91% of clinicians), often used alone or combined with DDAVP 2.

DDAVP's Limited Efficacy in HPS

The critical limitation is that DDAVP shows poor and unpredictable response in HPS patients, particularly those with HPS-1 mutations. Research specifically examining HPS patients reveals that DDAVP improved bleeding time in only 11% of pediatric HPS patients, with 89% maintaining severely prolonged bleeding times (>15 minutes) despite treatment 4. The HPS-1 gene mutation showed statistically significant correlation with poor DDAVP response (P=0.03) 4.

Even when DDAVP appears to work, response varies unpredictably between and within the same HPS patient across different procedures 5. One case report documented severe hemorrhagic sequelae requiring transfusion despite DDAVP prophylaxis at first delivery, though the same prophylaxis succeeded at second delivery 5.

Recommended Surgical Algorithm

Preoperative Preparation

1. Confirm HPS diagnosis and subtype (HPS-1 has poorest DDAVP response)
2. Obtain baseline coagulation studies: bleeding time, platelet function testing, fibrinogen levels
3. Arrange HLA-matched apheresis platelets to be immediately available 6
4. Avoid alloimmunization - use leukocyte-reduced blood products if transfusion needed, as alloimmunization creates barriers to future procedures including transplantation 7

Pharmacologic Protocol

Primary strategy:

• Tranexamic acid: 10-15 mg/kg IV loading dose 30 minutes before incision
• Followed by continuous infusion 1-5 mg/kg/hour throughout procedure 1, 8
• Continue until bleeding adequately controlled 8

Adjunctive consideration (optional):

• DDAVP 0.3 mcg/kg IV may be added if bleeding risk is extreme 9, though evidence suggests minimal benefit in HPS
• Administer 30 minutes before procedure if used 10, 6

Definitive hemostatic backup:

• Platelet transfusion remains the treatment of choice for major bleeding or surgical procedures in HPS 4
• Use HLA-matched apheresis platelets (1 unit) 6
• Administer intraoperatively if bleeding occurs despite pharmacologic measures

Local Hemostatic Measures

Apply topical hemostatic agents at surgical site:

• Avitene (microfibrillar collagen)
• Gelfoam packing
• Fibrin glue or thrombin gel 1, 6

Critical Pitfalls to Avoid

DDAVP-Specific Warnings

1. Do not rely on DDAVP as sole hemostatic agent in HPS - the 89% failure rate in HPS patients makes this dangerous 4
2. Water retention and hyponatremia risk - particularly concerning in elderly patients or with repeated dosing 11
3. Thromboembolic complications - though rare, DDAVP carries cardiovascular risks 9, 10
4. Tachyphylaxis - repeated dosing may lose effectiveness 11

Tranexamic Acid Precautions

1. Contraindicated with active intravascular clotting 12
2. Seizure risk - particularly at high doses; monitor for myoclonic movements 12
3. Ensure IV route only - intrathecal administration causes seizures and arrhythmias 12
4. Dose reduction in renal impairment:
   • Creatinine 1.36-2.83 mg/dL: 10 mg/kg twice daily
   • Creatinine 2.83-5.66 mg/dL: 10 mg/kg daily
   • Creatinine >5.66 mg/dL: 10 mg/kg every 48 hours 12

Platelet Transfusion Strategy

Do not delay platelet transfusion if pharmacologic measures fail. The case literature consistently shows successful hemostasis when platelets are used appropriately 6, 13, 7. One lung transplant recipient required extracorporeal membrane oxygenation with intraoperative prothrombin complex concentrate, platelet transfusion, and DDAVP - demonstrating that complex cases may need multimodal therapy 7.

Monitoring Requirements

• Visual assessment of surgical field jointly with surgeon to detect microvascular bleeding 1
• Platelet function testing if available, though results may not predict DDAVP response in HPS 9
• Fibrinogen levels - maintain >2.0 g/L for major procedures 1
• Hemoglobin monitoring - transfusion threshold of 8 g/dL for surgical patients 3

Postoperative Management

Continue tranexamic acid for 24 hours postoperatively if bleeding risk persists 8. Monitor for delayed bleeding, which can occur hours to days after procedures in platelet dysfunction disorders 14. Ensure clear communication between surgical and hematology teams regarding expected recovery timeline and discharge planning 14.